US20030093114A1 - Method for effecting hemostasis - Google Patents

Method for effecting hemostasis Download PDF

Info

Publication number
US20030093114A1
US20030093114A1 US10/008,052 US805201A US2003093114A1 US 20030093114 A1 US20030093114 A1 US 20030093114A1 US 805201 A US805201 A US 805201A US 2003093114 A1 US2003093114 A1 US 2003093114A1
Authority
US
United States
Prior art keywords
glucosamine
poly
biopolymer
closure pad
puncture wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US10/008,052
Inventor
Melvin Levinson
George Golik
Ernest Manzano
Raymond Diaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scion Cardio Vascular Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/008,052 priority Critical patent/US20030093114A1/en
Assigned to SCION CARDIO-VASCULAR, INC. reassignment SCION CARDIO-VASCULAR, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GOLIK, GEORGE, LEVINSON, MELVIN, DIAZ, RAYMOND, MANZANO, ERNEST
Priority to US10/267,902 priority patent/US20030148994A1/en
Priority to US10/267,940 priority patent/US20030153528A1/en
Priority to US10/286,614 priority patent/US6638296B2/en
Priority to US10/286,566 priority patent/US6890344B2/en
Priority to AU2002363798A priority patent/AU2002363798A1/en
Priority to PCT/US2002/036564 priority patent/WO2003041564A2/en
Publication of US20030093114A1 publication Critical patent/US20030093114A1/en
Priority to US11/125,765 priority patent/US20050222615A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00365—Plasters use
    • A61F2013/00412—Plasters use for use with needles, tubes or catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00365—Plasters use
    • A61F2013/00463—Plasters use haemostatic
    • A61F2013/00472—Plasters use haemostatic with chemical means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Definitions

  • the present invention relates to a method for local management of bleeding wounds and, more particularly, a method for rapidly controlling bleeding even in patients receiving hemodialysis and anticoagulation treatments.
  • the nurse or physician will create an opening into an artery or other vessel with a conventional catheter introducer or dilator. Additionally, the catheter is often twisted or otherwise manipulated as it is advanced to the treatment site, thereby causing a further enlargement of the incision or puncture in the body of the patient.
  • What is desired therefore is a simple, safe and relatively inexpensive method for managing bleeding wounds such as lacerations, abrasions, nose bleeds, vascular access sites, percutaneous catherters, or tubes and surgical debridement.
  • the method will provide a rapid control of bleeding even in patients receiving hemodialysis and anticoagulation treatments.
  • the present invention provides a method for effecting hemostasis at a puncture wound extending to a blood vessel.
  • the puncture wound may, or may not, have an introducer or catheter disposed therein.
  • the method includes applying pressure proximal to the puncture wound, and directing a cationic application surface of a closure pad against the puncture wound with force sufficient to prevent fluid from exiting the puncture wound, by collapsing the blood vessel.
  • the pressure proximal to the puncture wound is then removed. If an introducer or catheter is present, it is then removed from the puncture wound.
  • the method then includes maintaining the force on the closure pad against the wound for at least a first predetermined time period. Upon verification (usually visually) of hemostasis, the force to the pad is removed.
  • Dressing may be applied over the closure pad and the puncture wound. The dressing and the closure pad will then be removed after a second predetermined time period.
  • the application surface of the pad is a biopolymer of glucosamine, including but not limited to poly-N-acetylglucosamine.
  • the application surface is an acetate salt of a biopolymer of glucosamine.
  • the first predetermined time period is substantially proportional to the diameter of the introducer or the catheter.
  • the first predetermined time period is equal to about ten minutes.
  • the second predetermined time period is equal to about twenty-four hours.
  • the method of the present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form particularly, but not limited to, cases following removal of an introducer or a catheter from the puncture wound.
  • FIG. 1 is a side elevation view, partially in section, showing a catheter extending through a puncture wound into an artery of a patient, with the puncture wound extending through an epidermal and dermal layer of the patient's skin and through a wall of the artery;
  • FIG. 2 is a side elevation view, partially in section, showing the catheter removed from the puncture wound and a closure pad secured to the patient's skin over the puncture wound in accordance with a method of the present invention for effecting hemostasis;
  • FIG. 3 is a side elevation view, partially in section, showing the closure pad secured to the patient's skin over the puncture wound in accordance with the present invention, and hemostasis occurring within the puncture wound;
  • FIG. 4 is a flow chart illustrating the method of the present invention for effecting hemostasis in a puncture wound.
  • the present invention is described hereinafter with specific reference to the use of the present invention for sealing an incision or puncture wound leading to a blood vessel in a patient. It is contemplated that the present invention may be used with nearly any catheterization or other medical procedure such as laparoscopic or other minimally or less invasive surgeries wherein it is desirable to seal an incision or puncture wound in the patient to prevent the loss of the patient's body fluid therethrough.
  • FIGS. 1 through 3 a brief description of a conventional angiographic catheterization procedure through a femoral artery 10 of a patient is set forth herein and illustrated in FIGS. 1 through 3, for purposes of illustration.
  • an angiographic needle (not shown) is inserted percutaneously through the epidermal and dermal layer of the skin 12 of the patient at an angle to form an incision or puncture wound 14 .
  • the needle is inserted percutaneously into the skin 12 until the needle pierces the wall of the femoral artery 10 .
  • the puncture of the artery 10 by the needle is then confirmed by the physician and a small diameter guide wire (not shown) is inserted through a central lumen in the needle and the needle is withdrawn over the guide wire while pressure is applied to the artery 10 to limit the bleeding and prevent the formation of a hematoma at the incision site.
  • the catheter 16 and an outer introducer or catheter sheath are inserted over the guide wire.
  • the catheter 16 is advanced to the final location and the procedure is performed. Once the procedure has been completed, the catheter 16 is removed and a method according to the present invention for controlling bleeding from the puncture wound 14 is conducted as described hereinafter.
  • the method includes applying pressure proximal to the puncture wound 14 to at least partially collapse the blood vessel 10 , as shown at “A”, and directing a cationic biopolymer of glucosamine application surface of a closure pad 18 against the puncture wound 14 with force sufficient to substantially prevent fluid from exiting the puncture wound 14 , as shown at “B”. Then the pressure proximal to the puncture wound 14 is removed, as shown at “C”, and the catheter 16 is removed from the puncture wound 14 , as shown at “D”.
  • the method then includes maintaining the force on the closure pad 18 and against the wound 14 for at least a first predetermined time period, as shown at “E”, and removing the force on the closure pad, as shown at “G”, if hemostasis is verified, as shown at “F”. Hemostasis is generally verified visually.
  • a dressing (not shown), can also be applied over the closure pad 18 and the puncture wound 14 , as shown at “H”.
  • the dressing and the closure pad 18 are then removed after a second predetermined time period, as shown at “I”.
  • the application surface of, and in some forms of the invention, the entire closure pad 18 are preferably made substantially only of a cationic biopolymer of glucosamine provided in one or more of the following forms: poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine; an acetate salt of poly-D-glucosamine; poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine; and poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
  • the application surface is water soluble. Acidic environments other than an acetate salt, such as lactic acid, can also be incorporated
  • a cationic biopolymer of glucosamine is derived from chitosan, which is a collective term applied to deacetylated chitins in various stages of deacetylation and depolymerization.
  • Chitin is the structural polymer of the exo-skeleton of arthropods and cell walls of fungi, and is composed of poly-N-Acetyl glucosamine units. These are linked by Beta 1-4 glycosidic bonds into a linear polymer containing 2,000 to 3,000 units.
  • Chitosan is a derivative of solid waste from shell fish processing and can be extracted from fungus culture.
  • Chitin is generally isolated and purified by first dissolving away the inorganic material, calcium carbonate, by treatment with hydrochloric acid. After the protein material is removed by digestion with hot diluted alkali, the chitin is bleached with permanganate followed by treatment with oxalic acid. Partial deacetylization of chitin by treatment with concentrated alkali solution at 130 to 150 degrees centigrade yields products which are soluble in dilute acetic acid.
  • a common method to convert crab shell to Chitosan is as follows: The calcium carbonate is removed by immersing the shell in cold dilute hydrochloric acid, two to three hours are allowed for the reaction. The shell is then thoroughly rinsed with water. Protein is removed by treating the shell with caustic soda (3% strength). The shell is cooked in a 3% sodium hydroxide solution for a period of two hours at a temperature of 100° C. and at atmospheric pressure. The remains are rinsed thoroughly with water to remove all traces of sodium hydroxide and protein, and bleached with potassium permanganate solution and again rinsed with water.
  • the remains are then treated with oxalic acid to remove the permanganate solution, and then treated with a 40% caustic soda solution at 150° C. to partially deacetylate the chitosan.
  • various viscosities of chitosan can be produced.
  • the final pH of the chitosan solution is in the range of 4-5. It is possible to utilize chitosan in the following applications in various pH's and viscosities.
  • the ideal mode is a solution of 2 grams of chitosan per liter of acetic acid solution. This process is discussed in U.S. Pat. No. 4,394,373 to Malette et al., which is incorporated herein by reference.
  • the remainder of the closure pad 18 can be made of a material that supports and/or supplements the application surface.
  • the remainder of the closure pad 18 can, for example, comprise absorbent or non-absorbent material, and a rigid, semi-rigid or soft material.
  • the remainder of the closure pad 18 can, for example, comprise a plastic, a cellulose polymer, or other suitable material.
  • the application surface of, and in some forms of the invention, the entire closure pad 18 is soft and made of non-woven fibers.
  • the application surface and/or the entire closure pad 18 can be made of woven material, layers of woven material, and woven and non-woven layers.
  • the closure pad 18 Prior to use, the closure pad 18 is packed in a pouch (for example, made of foil, paper or Tyvek® material) and sterilized (for example, by E-beam radiation, ethylene oxide, or other suitable sterilization method, to a 10 ⁇ 6 sterility assurance level).
  • a pouch for example, made of foil, paper or Tyvek® material
  • sterilized for example, by E-beam radiation, ethylene oxide, or other suitable sterilization method, to a 10 ⁇ 6 sterility assurance level.
  • the first predetermined time period is substantially proportional to a diameter of the catheter 16 (or of a diameter of an introducer for the catheter, if the introducer is used), and thus the resulting puncture wound 14 .
  • the first predetermined time period is preferably equal to about ten minutes, although other time periods can be used.
  • the pressure is not removed from the closure pad 18 and the puncture wound 14 until hemostasis is confirmed. Thus force may need to be maintained on the closure pad 18 for longer than ten minutes.
  • the dressing can comprise gauze pads and tape, or other suitable dressings, placed over the closure pad.
  • the second predetermined time period is preferably equal to about twenty-four hours. After twenty-four hours, the dressing and the closure pad 18 are removed from the puncture wound. If hemostasis can not be confirmed after removal of the dressing and the closure pad, a new closure pad and dressing should be applied to the wound, until hemostasis is confirmed.
  • the method of the present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form after removal of a catheter from the puncture wound. Modification to above-described preferred embodiment of the presently disclosed invention may become apparent to those skilled in the art. The scope of the invention is therefore intended to be limited solely by the scope of the appended claims.

Abstract

A method for effecting hemostasis at a puncture wound, includes applying pressure proximal to the puncture wound, and directing a cationic biopolymer of glucosamine application surface of a closure pad against the puncture wound with force sufficient to prevent fluid from exiting the puncture wound. Then the pressure proximal to the puncture wound is removed and the force on the closure pad is maintained for at least a first predetermined time period. The force on the closure pad is removed if hemostasis is verified. The puncture wound may then be dressed over the closure pad, and the dressing and the closure pad removed after a second predetermined time period.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a method for local management of bleeding wounds and, more particularly, a method for rapidly controlling bleeding even in patients receiving hemodialysis and anticoagulation treatments. [0001]
    • BACKGROUND OF THE INVENTION
  • During catheterization procedures, the nurse or physician will create an opening into an artery or other vessel with a conventional catheter introducer or dilator. Additionally, the catheter is often twisted or otherwise manipulated as it is advanced to the treatment site, thereby causing a further enlargement of the incision or puncture in the body of the patient. [0002]
  • When the medical procedure is completed and the catheter is removed from the artery or other blood vessel, conventional practice has been to apply external pressure to the entry site until hemostasis occurs. Because many of the patients undergoing these procedures have been medicated with an anticoagulant such as heparin, the nurse may be required to apply external pressure to the incision site for an extended period of time period. The time period required to stop bleeding at the incision is not an efficient use of the nurses time period and a painful hematoma or unsightly bruise may still occur at the incision site because the artery will continue to bleed internally until clotting blocks the opening in the artery. [0003]
  • What is desired therefore is a simple, safe and relatively inexpensive method for managing bleeding wounds such as lacerations, abrasions, nose bleeds, vascular access sites, percutaneous catherters, or tubes and surgical debridement. Preferably, the method will provide a rapid control of bleeding even in patients receiving hemodialysis and anticoagulation treatments. [0004]
    • SUMMARY OF THE INVENTION
  • The present invention provides a method for effecting hemostasis at a puncture wound extending to a blood vessel. The puncture wound may, or may not, have an introducer or catheter disposed therein. The method includes applying pressure proximal to the puncture wound, and directing a cationic application surface of a closure pad against the puncture wound with force sufficient to prevent fluid from exiting the puncture wound, by collapsing the blood vessel. The pressure proximal to the puncture wound is then removed. If an introducer or catheter is present, it is then removed from the puncture wound. The method then includes maintaining the force on the closure pad against the wound for at least a first predetermined time period. Upon verification (usually visually) of hemostasis, the force to the pad is removed. Dressing may be applied over the closure pad and the puncture wound. The dressing and the closure pad will then be removed after a second predetermined time period. [0005]
  • According to one aspect of the present invention, the application surface of the pad is a biopolymer of glucosamine, including but not limited to poly-N-acetylglucosamine. In some forms of the invention, the application surface is an acetate salt of a biopolymer of glucosamine. [0006]
  • According to further aspect of the present invention, when an introducer or catheter is disposed in the wound, the first predetermined time period is substantially proportional to the diameter of the introducer or the catheter. According to another aspect, the first predetermined time period is equal to about ten minutes. According to an additional aspect, the second predetermined time period is equal to about twenty-four hours. [0007]
  • The method of the present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form particularly, but not limited to, cases following removal of an introducer or a catheter from the puncture wound. These and other features and benefits of the present disclosure will become more apparent upon reading the following specification in combination with the accompanying drawing figures. [0008]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a side elevation view, partially in section, showing a catheter extending through a puncture wound into an artery of a patient, with the puncture wound extending through an epidermal and dermal layer of the patient's skin and through a wall of the artery; [0009]
  • FIG. 2 is a side elevation view, partially in section, showing the catheter removed from the puncture wound and a closure pad secured to the patient's skin over the puncture wound in accordance with a method of the present invention for effecting hemostasis; [0010]
  • FIG. 3 is a side elevation view, partially in section, showing the closure pad secured to the patient's skin over the puncture wound in accordance with the present invention, and hemostasis occurring within the puncture wound; and [0011]
  • FIG. 4 is a flow chart illustrating the method of the present invention for effecting hemostasis in a puncture wound.[0012]
  • Like reference characters designate identical or corresponding components and units throughout the several views. [0013]
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The present invention is described hereinafter with specific reference to the use of the present invention for sealing an incision or puncture wound leading to a blood vessel in a patient. It is contemplated that the present invention may be used with nearly any catheterization or other medical procedure such as laparoscopic or other minimally or less invasive surgeries wherein it is desirable to seal an incision or puncture wound in the patient to prevent the loss of the patient's body fluid therethrough. [0014]
  • In order to more fully understand and appreciate the present invention, a brief description of a conventional angiographic catheterization procedure through a [0015] femoral artery 10 of a patient is set forth herein and illustrated in FIGS. 1 through 3, for purposes of illustration. In such a procedure, an angiographic needle (not shown) is inserted percutaneously through the epidermal and dermal layer of the skin 12 of the patient at an angle to form an incision or puncture wound 14. The needle is inserted percutaneously into the skin 12 until the needle pierces the wall of the femoral artery 10. The puncture of the artery 10 by the needle is then confirmed by the physician and a small diameter guide wire (not shown) is inserted through a central lumen in the needle and the needle is withdrawn over the guide wire while pressure is applied to the artery 10 to limit the bleeding and prevent the formation of a hematoma at the incision site. The catheter 16 and an outer introducer or catheter sheath (not shown) are inserted over the guide wire. Next, the catheter 16 is advanced to the final location and the procedure is performed. Once the procedure has been completed, the catheter 16 is removed and a method according to the present invention for controlling bleeding from the puncture wound 14 is conducted as described hereinafter.
  • Referring also to FIG. 4, the method includes applying pressure proximal to the [0016] puncture wound 14 to at least partially collapse the blood vessel 10, as shown at “A”, and directing a cationic biopolymer of glucosamine application surface of a closure pad 18 against the puncture wound 14 with force sufficient to substantially prevent fluid from exiting the puncture wound 14, as shown at “B”. Then the pressure proximal to the puncture wound 14 is removed, as shown at “C”, and the catheter 16 is removed from the puncture wound 14, as shown at “D”. The method then includes maintaining the force on the closure pad 18 and against the wound 14 for at least a first predetermined time period, as shown at “E”, and removing the force on the closure pad, as shown at “G”, if hemostasis is verified, as shown at “F”. Hemostasis is generally verified visually.
  • A dressing (not shown), can also be applied over the [0017] closure pad 18 and the puncture wound 14, as shown at “H”. The dressing and the closure pad 18 are then removed after a second predetermined time period, as shown at “I”.
  • Preferably, the application surface of, and in some forms of the invention, the [0018] entire closure pad 18, are preferably made substantially only of a cationic biopolymer of glucosamine provided in one or more of the following forms: poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine; an acetate salt of poly-D-glucosamine; poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine; and poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine. In forms including an acetate salt, the application surface is water soluble. Acidic environments other than an acetate salt, such as lactic acid, can also be incorporated as part of the biopolymer of glucosamine.
  • A cationic biopolymer of glucosamine is derived from chitosan, which is a collective term applied to deacetylated chitins in various stages of deacetylation and depolymerization. Chitin is the structural polymer of the exo-skeleton of arthropods and cell walls of fungi, and is composed of poly-N-Acetyl glucosamine units. These are linked by Beta 1-4 glycosidic bonds into a linear polymer containing 2,000 to 3,000 units. [0019]
  • Chitosan is a derivative of solid waste from shell fish processing and can be extracted from fungus culture. Chitin is generally isolated and purified by first dissolving away the inorganic material, calcium carbonate, by treatment with hydrochloric acid. After the protein material is removed by digestion with hot diluted alkali, the chitin is bleached with permanganate followed by treatment with oxalic acid. Partial deacetylization of chitin by treatment with concentrated alkali solution at 130 to 150 degrees centigrade yields products which are soluble in dilute acetic acid. [0020]
  • A common method to convert crab shell to Chitosan, for example, is as follows: The calcium carbonate is removed by immersing the shell in cold dilute hydrochloric acid, two to three hours are allowed for the reaction. The shell is then thoroughly rinsed with water. Protein is removed by treating the shell with caustic soda (3% strength). The shell is cooked in a 3% sodium hydroxide solution for a period of two hours at a temperature of 100° C. and at atmospheric pressure. The remains are rinsed thoroughly with water to remove all traces of sodium hydroxide and protein, and bleached with potassium permanganate solution and again rinsed with water. The remains are then treated with oxalic acid to remove the permanganate solution, and then treated with a 40% caustic soda solution at 150° C. to partially deacetylate the chitosan. This results in the formation of chitosan. By varying the amount of deacetylation, various viscosities of chitosan can be produced. The final pH of the chitosan solution is in the range of 4-5. It is possible to utilize chitosan in the following applications in various pH's and viscosities. However, the ideal mode is a solution of 2 grams of chitosan per liter of acetic acid solution. This process is discussed in U.S. Pat. No. 4,394,373 to Malette et al., which is incorporated herein by reference. [0021]
  • If only the application surface of the [0022] closure pad 18 is made of a cationic biopolymer of glucosamine, then the remainder of the closure pad 18 can be made of a material that supports and/or supplements the application surface. The remainder of the closure pad 18 can, for example, comprise absorbent or non-absorbent material, and a rigid, semi-rigid or soft material. The remainder of the closure pad 18 can, for example, comprise a plastic, a cellulose polymer, or other suitable material.
  • In addition, the application surface of, and in some forms of the invention, the [0023] entire closure pad 18, is soft and made of non-woven fibers. However, the application surface and/or the entire closure pad 18, can be made of woven material, layers of woven material, and woven and non-woven layers.
  • Prior to use, the [0024] closure pad 18 is packed in a pouch (for example, made of foil, paper or Tyvek® material) and sterilized (for example, by E-beam radiation, ethylene oxide, or other suitable sterilization method, to a 10−6 sterility assurance level).
  • The first predetermined time period is substantially proportional to a diameter of the catheter [0025] 16 (or of a diameter of an introducer for the catheter, if the introducer is used), and thus the resulting puncture wound 14. In general, however, the first predetermined time period is preferably equal to about ten minutes, although other time periods can be used. In any event, the pressure is not removed from the closure pad 18 and the puncture wound 14 until hemostasis is confirmed. Thus force may need to be maintained on the closure pad 18 for longer than ten minutes. The dressing can comprise gauze pads and tape, or other suitable dressings, placed over the closure pad.
  • The second predetermined time period is preferably equal to about twenty-four hours. After twenty-four hours, the dressing and the [0026] closure pad 18 are removed from the puncture wound. If hemostasis can not be confirmed after removal of the dressing and the closure pad, a new closure pad and dressing should be applied to the wound, until hemostasis is confirmed.
  • The method of the present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form after removal of a catheter from the puncture wound. Modification to above-described preferred embodiment of the presently disclosed invention may become apparent to those skilled in the art. The scope of the invention is therefore intended to be limited solely by the scope of the appended claims. [0027]

Claims (40)

1. A method for effecting hemostasis at a puncture wound extending to a blood vessel, comprising:
A) applying pressure proximal to the puncture wound in order to at least partially collapse the blood vessel;
B) directing an application surface of a closure pad against the puncture wound with force sufficient to substantially prevent fluid from exiting the puncture wound, wherein the application surface is a cationic biopolymer of glucosamine;
C) removing the pressure proximal to the puncture wound;
D) maintaining the force on the closure pad against the puncture wound for at least a first predetermined time period;
E) removing the force on the closure pad upon verification of hemostasis.
2. The method of claim 1, wherein the entire closure pad including the application surface comprises a cationic biopolymer of glucosamine.
3. The method of claim 2, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.
4. The method of claim 3, wherein the closure pad is made of non-woven fibers.
5. The method of claim 2, wherein the biopolymer of glucosamine is poly-D-glucosamine.
6. The method of claim 5, wherein the closure pad is made of non-woven fibers.
7. The method of claim 2, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.
8. The method of claim 7, wherein the closure pad is made of non-woven fibers.
9. The method of claim 2, wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.
10. The method of claim 9, wherein the closure pad is made of non-woven fibers.
11. The method of claim 2, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.
12. The method of claim 11, wherein the closure pad is made of non-woven fibers.
13. The method of claim 2, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.
14. The method of claim 13, wherein the closure pad is made of non-woven fibers.
15. The method of claim 1, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
16. The method of claim 15, wherein the closure pad is made of non-woven fibers.
17. The method of claim 2, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
18. The method of claim 17, wherein the closure pad is made of non-woven fibers.
19. The method of claim 2, wherein the application surface comprises a cationic biopolymer of glucosamine and a remainder of the closure pad comprises another material.
20. The method of claim 19, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.
21. The method of claim 20, wherein the application surface is made of non-woven fibers.
22. The method of claim 19, wherein the biopolymer of glucosamine is poly-D-glucosamine.
23. The method of claim 22, wherein the application surface is made of non-woven fibers.
24. The method of claim 19, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.
25. The method of claim 24, wherein the application surface is made of non-woven fibers.
26. The method of claim 19, wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.
27. The method of claim 26, wherein the application surface is made of non-woven fibers.
28. The method of claim 19, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.
29. The method of claim 28, wherein the application surface is made of non-woven fibers.
30. The method of claim 19, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.
31. The method of claim 30, wherein the application surface is made of non-woven fibers.
32. The method of claim 19, wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
33. The method of claim 32, wherein the application surface is made of non-woven fibers.
34. The method of claim 19, wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
35. The method of claim 34, wherein the application surface is made of non-woven fibers.
36. The method of claim 1, wherein the first predetermined time period is equal to about ten minutes.
37. The method of claim 1, wherein an introducer having an outer diameter is disposed in the puncture wound and removed from the wound prior to removing the pressure proximal to the wound, and wherein the first predetermined time period is substantially proportional to the diameter of the introducer.
38. The method of claim 1, further comprising:
applying a dressing over the closure pad and the puncture wound; and
removing the dressing and the closure pad from the puncture wound after a second predetermined time period.
39. The method of claim 38, wherein the second predetermined time period is equal to about twenty-four hours.
40. The method of claim 38, wherein the dressing includes gauze.
US10/008,052 2001-11-13 2001-11-13 Method for effecting hemostasis Pending US20030093114A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US10/008,052 US20030093114A1 (en) 2001-11-13 2001-11-13 Method for effecting hemostasis
US10/267,902 US20030148994A1 (en) 2001-11-13 2002-10-09 Hemostatic composition
US10/267,940 US20030153528A1 (en) 2001-11-13 2002-10-09 Hemostatic bone wax composition
US10/286,614 US6638296B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method
US10/286,566 US6890344B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method
AU2002363798A AU2002363798A1 (en) 2001-11-13 2002-11-13 Method for effecting hemostasis
PCT/US2002/036564 WO2003041564A2 (en) 2001-11-13 2002-11-13 Method for effecting hemostasis
US11/125,765 US20050222615A1 (en) 2001-11-13 2005-05-10 Hemostasis pad and method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/008,052 US20030093114A1 (en) 2001-11-13 2001-11-13 Method for effecting hemostasis

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US10/267,902 Continuation-In-Part US20030148994A1 (en) 2001-11-13 2002-10-09 Hemostatic composition
US10/267,940 Continuation-In-Part US20030153528A1 (en) 2001-11-13 2002-10-09 Hemostatic bone wax composition
US10/286,614 Continuation-In-Part US6638296B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method
US10/286,566 Continuation-In-Part US6890344B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method

Publications (1)

Publication Number Publication Date
US20030093114A1 true US20030093114A1 (en) 2003-05-15

Family

ID=21729584

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/008,052 Pending US20030093114A1 (en) 2001-11-13 2001-11-13 Method for effecting hemostasis
US10/267,902 Abandoned US20030148994A1 (en) 2001-11-13 2002-10-09 Hemostatic composition
US10/267,940 Abandoned US20030153528A1 (en) 2001-11-13 2002-10-09 Hemostatic bone wax composition
US10/286,566 Expired - Lifetime US6890344B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method
US10/286,614 Expired - Lifetime US6638296B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method
US11/125,765 Abandoned US20050222615A1 (en) 2001-11-13 2005-05-10 Hemostasis pad and method

Family Applications After (5)

Application Number Title Priority Date Filing Date
US10/267,902 Abandoned US20030148994A1 (en) 2001-11-13 2002-10-09 Hemostatic composition
US10/267,940 Abandoned US20030153528A1 (en) 2001-11-13 2002-10-09 Hemostatic bone wax composition
US10/286,566 Expired - Lifetime US6890344B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method
US10/286,614 Expired - Lifetime US6638296B2 (en) 2001-11-13 2002-11-01 Hemostasis pad and method
US11/125,765 Abandoned US20050222615A1 (en) 2001-11-13 2005-05-10 Hemostasis pad and method

Country Status (3)

Country Link
US (6) US20030093114A1 (en)
AU (1) AU2002363798A1 (en)
WO (1) WO2003041564A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065877A2 (en) * 2002-02-04 2003-08-14 Damage Control Surgical Technologies, Inc. Method and apparatus for improved hemostasis and damage control operations
WO2004041064A2 (en) * 2002-10-30 2004-05-21 Rossen Joel S Simplified one-handed preemptive medical procedure site dressing to prevent sharps injuries and exposure to bloodborne pathogens
US7943810B2 (en) 2003-02-04 2011-05-17 Buckman Robert F Method and apparatus for hemostasis
US7955616B2 (en) * 2003-09-23 2011-06-07 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
EP1677664B1 (en) * 2003-09-23 2014-07-30 Orthocon Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US20050267520A1 (en) 2004-05-12 2005-12-01 Modesitt D B Access and closure device and method
US7678133B2 (en) 2004-07-10 2010-03-16 Arstasis, Inc. Biological tissue closure device and method
US20080015481A1 (en) * 2005-05-04 2008-01-17 Bergin Patrick J Hemostatic bandage and method of use
US20060276838A1 (en) * 2005-06-07 2006-12-07 Wensel Jeffrey P Vascular puncture sealing method, apparatus, and system
US20060276836A1 (en) * 2005-06-07 2006-12-07 Bergin Patrick J Hemostatic wire guided bandage and method of use
US7622628B2 (en) * 2005-05-04 2009-11-24 Innovasa Corporation Hemostatic wire guided bandage and method of use
AU2006247355B2 (en) 2005-05-12 2013-01-10 Arstasis, Inc. Access and closure device and method
US20070122361A1 (en) * 2005-11-29 2007-05-31 Weitao Jia Tooth colorant and whitener, method of manufacture, and method of use thereof
US20070154509A1 (en) * 2005-12-30 2007-07-05 Wilcher Steve A Adsorbent-Containing Hemostatic Devices
US20070154510A1 (en) * 2005-12-30 2007-07-05 Wilcher Steve A Adsorbent-Containing Hemostatic Devices
US8277837B2 (en) 2006-01-11 2012-10-02 Entegrion, Inc. Hemostatic textile
US7645252B2 (en) 2006-05-16 2010-01-12 Barbara Brooke Jennings-Spring Body or plant part dressing
US7905852B2 (en) 2006-05-16 2011-03-15 Barbara Jennings-Spring Skin-contacting-adhesive free dressing
US20090287133A1 (en) * 2006-06-06 2009-11-19 Lagreca Sr Alfred J Disposable or Reclosable Wound or Skin Condition Dressing and Treatment System
US20080097270A1 (en) * 2006-08-25 2008-04-24 Utterberg David S Resilient hemostasis devices
US20080063697A1 (en) * 2006-09-08 2008-03-13 Bedard Robert L Use of Unactivated Calcium Exchanged Zeolites in Hemostatic Devices and Products
WO2008039879A2 (en) * 2006-09-26 2008-04-03 Innovasa Corporation Hemostatic bandage
US8623842B2 (en) 2006-09-27 2014-01-07 Hemostasis, Llc Hemostatic agent and method
US8100937B2 (en) 2006-10-10 2012-01-24 Smalling Medical Ventures, Llc Pressure assist system for facilitating vascular hemostasis, and associated method
US7931651B2 (en) 2006-11-17 2011-04-26 Wake Lake University Health Sciences External fixation assembly and method of use
US20080145455A1 (en) * 2006-12-13 2008-06-19 Bedard Robert L Combination of Inorganic Hemostatic Agents with Other Hemostatic Agents
US8932560B2 (en) * 2007-09-04 2015-01-13 University of Maryland, College Parke Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells
US9066885B2 (en) * 2007-03-16 2015-06-30 University Of Maryland, College Park Advanced functional biocompatible polymeric matrix containing nano-compartments
US8597253B2 (en) 2007-04-20 2013-12-03 Bard Access Systems Huber needle with safety sheath
US20090047366A1 (en) * 2007-08-15 2009-02-19 Bedard Robert L Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants
US8883194B2 (en) * 2007-11-09 2014-11-11 Honeywell International, Inc. Adsorbent-containing hemostatic devices
US8795718B2 (en) * 2008-05-22 2014-08-05 Honeywell International, Inc. Functional nano-layered hemostatic material/device
US9289193B2 (en) 2008-07-18 2016-03-22 Wake Forest University Health Sciences Apparatus and method for cardiac tissue modulation by topical application of vacuum to minimize cell death and damage
WO2010011695A1 (en) 2008-07-21 2010-01-28 Arstasis, Inc. Devices, methods, and kits for forming tracts in tissue
US20110108199A1 (en) * 2009-11-10 2011-05-12 Tyco Healthcare Group Lp Hemostatic Tapes and Dispensers Therefor
US20110112572A1 (en) * 2009-11-10 2011-05-12 Tyco Healthcare Group Lp Hemostatic Tapes and Dispensers Therefor
CA2780898A1 (en) 2009-11-13 2011-05-19 University Of Maryland, College Park Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds
CN101862469B (en) * 2010-05-28 2013-03-13 武汉人福医疗用品有限公司 Chitosan derivative quick hemostasis granules and preparation method thereof
US8302323B2 (en) 2010-06-21 2012-11-06 Confluent Surgical, Inc. Hemostatic patch
CA2819186C (en) * 2010-07-14 2018-06-19 Bard Access Systems, Inc. A dressing device for use with a cannula or a catheter
US8664199B2 (en) 2010-08-13 2014-03-04 University Of Maryland, College Park Method and system for reversal of interactions between hydrophobically modified biopolymers and vesicles or cell membranes
US20140066894A1 (en) 2010-09-10 2014-03-06 C. R. Bard, Inc. Self-Sealing Pad for a Needle-Based Infusion Set
JP2013539665A (en) 2010-09-10 2013-10-28 シー・アール・バード・インコーポレーテッド System for isolating needle-based infusion sets
US10525234B2 (en) 2010-09-10 2020-01-07 C. R. Bard, Inc. Antimicrobial/haemostatic interface pad for placement between percutaneously placed medical device and patient skin
US9427360B2 (en) 2010-11-04 2016-08-30 W. Jerry Mezger Hemostatic fabric
US8858883B2 (en) 2010-12-02 2014-10-14 University Of Maryland, College Park Method and system for capture and use of intact vesicles on electrodeposited hydrophobically modified biopolymer films
US9561300B2 (en) 2011-09-26 2017-02-07 Yes, Inc. Hemostatic compositions and dressings for bleeding
US20130317438A1 (en) 2012-05-25 2013-11-28 Arstasis, Inc. Vascular access configuration
US20130317481A1 (en) 2012-05-25 2013-11-28 Arstasis, Inc. Vascular access configuration
US8658193B2 (en) * 2012-06-08 2014-02-25 Robert J. Greenwald Styptic storage and delivery
WO2014015347A1 (en) 2012-07-20 2014-01-23 Aegis Women's Health Technologies Compositions and methods for preventing infectious diseases in females
US8969649B2 (en) * 2012-08-10 2015-03-03 Ethicon, Inc. Integrated dressing device
WO2014137824A1 (en) * 2013-03-07 2014-09-12 Life Sciences Llc Apparatus & method for wound infection prevention
US9616088B2 (en) 2013-03-13 2017-04-11 Gel-E, Inc. Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells
US8961479B2 (en) 2013-03-19 2015-02-24 Biolife, L.L.C. Hemostatic device and method
US20150057640A1 (en) * 2013-08-22 2015-02-26 Evelyn M. Tarkington Circular bandage for drain tube
US10195399B2 (en) 2013-10-29 2019-02-05 Avent, Inc. Catheter securement device
US9764116B2 (en) 2013-12-30 2017-09-19 Avent, Inc. Catheter insertion site plug
US10556093B2 (en) 2013-12-31 2020-02-11 Confluence, LLC Medical devices, dressings, and methods for closing openings in tissue
US10406255B2 (en) 2014-05-28 2019-09-10 Highland Industries, Inc. Hemostatic textile
US11627795B2 (en) 2017-02-14 2023-04-18 G-Tech Llc Shoulder transfer weight support system and face shield
JP7326258B2 (en) * 2018-05-16 2023-08-15 テルモ株式会社 compression device
CN110538024B (en) * 2019-09-03 2022-06-14 重庆市渝北区人民医院 Portable medical pressurizing application device, use method and application
WO2021134005A1 (en) * 2019-12-27 2021-07-01 Hg Medical Technologies Llc Iontophoretic wound treatment device
US11272941B1 (en) 2020-08-07 2022-03-15 William P Buchanan Secondary device holder and compression system, method of making and using the same

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632754A (en) * 1968-02-12 1972-01-04 Lescarden Ltd Use of chitin for promoting wound healing
US4059097A (en) * 1976-11-03 1977-11-22 American Cyanamid Company Method of minimizing tissue reaction during surgery with chitin
US4394373A (en) * 1981-04-06 1983-07-19 Malette William Graham Method of achieving hemostasis
US4981133A (en) * 1989-10-10 1991-01-01 Rollband Ernest J Pressure bandage for puncture wounds with a target marketing
US5203764A (en) * 1985-10-04 1993-04-20 Minnesota Mining And Manufacturing Company Foam pads useful in wound management
US5269803A (en) * 1992-04-10 1993-12-14 Gtr Patent, Inc. Hemostasis pressure pad band
US5310402A (en) * 1990-12-03 1994-05-10 Rollband Ernest J Temporary bandage tape
US5324252A (en) * 1991-03-25 1994-06-28 Minnesota Mining And Manufacturing Company Foam pads useful in wound management
US5336219A (en) * 1993-03-23 1994-08-09 Medi-Flex Hospital Products, Inc. Skin closure system
US5486195A (en) * 1993-07-26 1996-01-23 Myers; Gene Method and apparatus for arteriotomy closure
US5510102A (en) * 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US5665107A (en) * 1993-09-28 1997-09-09 Hemodynamics, Inc. Surface opening adhesive sealer
US5985434A (en) * 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
US6060461A (en) * 1999-02-08 2000-05-09 Drake; James Franklin Topically applied clotting material
US20010001316A1 (en) * 1997-12-17 2001-05-17 Closys Corporation Clotting cascade initiating apparatus and methods of use and methods of closing wounds
US6234989B1 (en) * 1995-06-07 2001-05-22 Gambro, Inc. Extracorporeal blood processing methods and apparatus
US20020015724A1 (en) * 1998-08-10 2002-02-07 Chunlin Yang Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
US20020062104A1 (en) * 1999-09-23 2002-05-23 Mark Ashby Depth and puncture control for blood vessel hemostasis system

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1027501B (en) * 1968-12-06 1978-12-20 Muzzarelli Weckx M G F CHITIN CHITOSAN AND DERIVATIVES USED AS CHROMATOGRAPHIC SUPPORTS AND AS ADSORBENTS FOR THE COLLECTION OF IONS FROM WATER AND ORGANIC SOLUTIONS FROM DRINKING AND SEA WATER
US3969189A (en) * 1971-12-14 1976-07-13 Kumiai Chemical Industry Co., Ltd. Cell wall-lysing complex enzymes and a process for the production thereof
US3811438A (en) 1972-03-30 1974-05-21 G Economou Adhesive tapes and bandages
US4532134A (en) * 1981-04-06 1985-07-30 Malette William Graham Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound
US4833238A (en) * 1986-12-16 1989-05-23 E. I. Du Pont De Nemours And Company High strength fibers from chitin derivatives
FR2616318A1 (en) * 1987-06-15 1988-12-16 Centre Nat Rech Scient ARTIFICIAL SKIN AND PROCESS FOR PREPARING THE SAME
US4784653A (en) * 1987-06-22 1988-11-15 Johnson & Johnson Patient Care, Inc. Absorbent adhesive dressing
US5086764A (en) * 1989-04-13 1992-02-11 Thomas Gilman Absorbent dressing
US5429591A (en) * 1991-07-22 1995-07-04 Nitto Denko Corporation Absorbent dressing having backing and continuous adhesive layer
US5375588A (en) * 1992-08-17 1994-12-27 Yoon; Inbae Method and apparatus for use in endoscopic procedures
US5683354A (en) * 1993-07-06 1997-11-04 Levy; Raymond H. Adhesive bandage for a digit of a human hand or foot
US5714543A (en) * 1994-01-13 1998-02-03 Bristol-Myers Squibb Company Water soluble polymer additives for polyurethane-based pressure sensitive adhesives
US5533962A (en) * 1995-05-12 1996-07-09 Peterman; Shadi Ringless adhesive bandage
US5836970A (en) 1996-08-02 1998-11-17 The Kendall Company Hemostatic wound dressing
US5807341A (en) * 1996-12-11 1998-09-15 Team Medical Llc Medical catheter dressing device
US6596699B2 (en) * 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
JP4703816B2 (en) 1999-06-08 2011-06-15 エシコン・インコーポレイテッド Surgical knitting mesh
US6586651B2 (en) * 1999-11-01 2003-07-01 John Patrick Sullivan Adhensive bandage with soft, three-dimensional toy
US7012169B2 (en) * 2000-04-06 2006-03-14 Kimberly-Clark Worldwide, Inc. Disposable finger sleeve for appendages
US6316686B1 (en) * 2000-06-20 2001-11-13 Timothy N. Byrd Medical pressure dressing and process

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632754A (en) * 1968-02-12 1972-01-04 Lescarden Ltd Use of chitin for promoting wound healing
US4059097A (en) * 1976-11-03 1977-11-22 American Cyanamid Company Method of minimizing tissue reaction during surgery with chitin
US4394373A (en) * 1981-04-06 1983-07-19 Malette William Graham Method of achieving hemostasis
US5203764A (en) * 1985-10-04 1993-04-20 Minnesota Mining And Manufacturing Company Foam pads useful in wound management
US4981133A (en) * 1989-10-10 1991-01-01 Rollband Ernest J Pressure bandage for puncture wounds with a target marketing
US5310402A (en) * 1990-12-03 1994-05-10 Rollband Ernest J Temporary bandage tape
US5324252A (en) * 1991-03-25 1994-06-28 Minnesota Mining And Manufacturing Company Foam pads useful in wound management
US5269803A (en) * 1992-04-10 1993-12-14 Gtr Patent, Inc. Hemostasis pressure pad band
US5336219A (en) * 1993-03-23 1994-08-09 Medi-Flex Hospital Products, Inc. Skin closure system
US5486195A (en) * 1993-07-26 1996-01-23 Myers; Gene Method and apparatus for arteriotomy closure
US5665107A (en) * 1993-09-28 1997-09-09 Hemodynamics, Inc. Surface opening adhesive sealer
US5510102A (en) * 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US6234989B1 (en) * 1995-06-07 2001-05-22 Gambro, Inc. Extracorporeal blood processing methods and apparatus
US5985434A (en) * 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
US20010001316A1 (en) * 1997-12-17 2001-05-17 Closys Corporation Clotting cascade initiating apparatus and methods of use and methods of closing wounds
US20020015724A1 (en) * 1998-08-10 2002-02-07 Chunlin Yang Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
US6060461A (en) * 1999-02-08 2000-05-09 Drake; James Franklin Topically applied clotting material
US20020062104A1 (en) * 1999-09-23 2002-05-23 Mark Ashby Depth and puncture control for blood vessel hemostasis system

Also Published As

Publication number Publication date
US20030093115A1 (en) 2003-05-15
US6890344B2 (en) 2005-05-10
WO2003041564A3 (en) 2003-12-04
US20030093075A1 (en) 2003-05-15
AU2002363798A1 (en) 2003-05-26
WO2003041564A2 (en) 2003-05-22
US6638296B2 (en) 2003-10-28
US20030153528A1 (en) 2003-08-14
US20050222615A1 (en) 2005-10-06
US20030148994A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
US20030093114A1 (en) Method for effecting hemostasis
US5437292A (en) Method for sealing blood vessel puncture sites
US20200197019A1 (en) Temporary occlusion balloon devices, systems and methods for preventing flow through a vascular perforation
EP1392181B1 (en) Method and apparatus for sealing access
Hoekstra et al. Percutaneous microcrystalline chitosan application for sealing arterial puncture sites
US10434212B2 (en) Degradable haemostat composition
EP2233157A1 (en) A biocompatible denatured starch sponge material
EP3003411B1 (en) Degradable haemostat composition
US20060282046A1 (en) Device and method for subcutaneous delivery of blood clotting agent
EP3334352A1 (en) Temporary occlusion balloon devices and methods for preventing blood flow through a vascular perforation
CN114014953B (en) Functionalized chitosan microsphere and preparation method and application thereof
JP6807922B2 (en) Biocompatible carboxymethyl cellulose matrix (BCM) for hemostasis, tissue barrier, wound healing, and cosmetology
US20110224713A1 (en) Slotted introducer needle and method for accessing a body lumen
CN106822987A (en) A kind of porous ball hemostatic material preparation method of shitosan alginate
CN107412842B (en) Preparation method of alginate wound dressing with thrombin
Khanna et al. Recommendations for Treatment of Exit-Site P a Thology
CN109010906B (en) Biological glue for promoting postoperative wound local hemostasis and promoting postoperative wound epithelization and working method thereof
US8591451B2 (en) Surgical methods, devices, and kits
CN204050019U (en) Hemostatic and antibacterial dressing plaster
CN114269350A (en) Topical hemostatic compositions
US20200000645A1 (en) Method for reducing blood loss
Manea et al. Nasal packing in endonasal surgery-a literature review
CN103211682A (en) Hemostatic material
CN117599235A (en) Application of Floccuronic acid polysaccharide in preparation of liquid hemostatic material for treating non-compressible hemorrhage and secondary hemorrhage
CN112138204A (en) Bone hemostatic material

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCION CARDIO-VASCULAR, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEVINSON, MELVIN;GOLIK, GEORGE;MANZANO, ERNEST;AND OTHERS;REEL/FRAME:012612/0875;SIGNING DATES FROM 20011114 TO 20011115

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED